Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosis.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

We report two cases of patients with relapsing-remitting multiple sclerosis with early-onset thrombocytopenia and autoimmune thyroid disease after the first treatment course with 60-mg alemtuzumab.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Mult. Scler.

Title: Multiple sclerosis (Houndmills, Basingstoke, England)

Publisher: SAGE Publications

ISSN (Electronic): 1477-0970

ISSN (Print): 1352-4585

Publication date (Electronic): Aug 2016

Volume: 22

Issue: 9

Affiliations

[1 ] Center for Neurology, Asklepios Hospitals Schildautal, Seesen, Germany/Departments of Neurology and Haematology, University of Duisburg-Essen, Duisburg, Germany mark.obermann@uni-due.de.

[2 ] Department of Neurology, University of Münster, Münster, Germany.

[3 ] Departments of Neurology and Haematology, University of Duisburg-Essen, Duisburg, Germany.

Article

Publisher Item ID: 1352458516638558

DOI: 10.1177/1352458516638558

PubMed ID: 26980848

SO-VID: 5f7102e1-29d6-4519-90ed-26dd0ce9f918

History

Keywords: treatment safety,side effects,risk factors,multiple sclerosis,immune thrombocytopenia,early-onset,adverse events,Alemtuzumab

Data availability:

Keywords: treatment safety, side effects, risk factors, multiple sclerosis, immune thrombocytopenia, early-onset, adverse events, Alemtuzumab

Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosis.

Read this article at

Abstract

Related collections

Cardiovascular Innovations and Applications

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Cited by 7